68Ga-DOTATATE在无神经内分泌肿瘤患者中的全身PBPK模型
本研究基于41例无生长抑素受体过表达肿瘤患者的68Ga-DOTATATE PET/CT数据,构建全身生理药代动力学(PBPK)模型描述药物器官分布。模型纳入受体内化、再循环、胞内酶解及肾清除,估算脾、肝、甲状腺的SSTR2量分别为4.40、7.80和0.0108 nmol。组织分布变异主要归因于SSTR2表达差异和给药肽量不同。
要点
- PBPK模型可描述68Ga-DOTATATE在无NET患者中的器官分布。
- 脾、肝、甲状腺SSTR2量估算为4.40、7.80、0.0108 nmol。
- 分布变异主要由SSTR2表达和给药肽量差异解释。
核心结论
- 68Ga-DOTATATE的体内分布可用全身PBPK模型描述,组织分布主要取决于SSTR2器官表达变异和给药肽量差异。
研究设计与样本
- 纳入41例无任何可检测的生长抑素受体过表达肿瘤患者的临床68Ga-DOTATATE PET/CT数据。
- 扫描在静脉弹丸注射68Ga-DOTATATE后45分钟(范围30-60分钟)进行。
- 从PET扫描获取脾、肝、甲状腺及血液活度并计算DOTATATE浓度,构建含内化、受体再循环、胞内酶解和肾清除的全身PBPK模型。
主要发现
- 68Ga-DOTATATE给药肽量中位数12.3 µg(范围8.05-16.9 µg),标记活度92.7 MBq(范围43.4-129.9 MBq)。
- 脾、肝、甲状腺的SSTR2量估算分别为4.40、7.80和0.0108 nmol。
- 观察到的器官浓度变异最佳由SSTR2表达变异和给药肽量差异描述。
临床怎么用
- 该PBPK模型可用于理解无NET患者中68Ga-DOTATATE的器官分布变异,辅助解释生理性摄取差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physiologically based pharmacokinetic (PBPK) models combine drug-specific information with prior knowledge on the physiology and biology at the organism level. Whole-body PBPK models contain an explicit representation of the organs and tissue and are a tool to predict pharmacokinetic behavior of drugs. The aim of this study was to develop a PBPK model to describe organ distribution of 68Ga-DOTATATE in a population of patients without detectable neuroendocrine tumors (NETs). METHODS: Clinical 68Ga-DOTATATE PET/CT data from 41 patients without any detectable somatostatin receptor (SSTR) overexpressing tumors were included. Scans were performed at 45 min (range 30-60 min) after intravenous bolus injection of 68Ga-DOTATATE. Organ (spleen, liver, thyroid) and blood activity levels were derived from PET scans, and corresponding DOTATATE concentrations were calculated. A whole-body PBPK model was developed, including an internalization reaction, receptor recycling, enzymatic reaction for intracellular degradation and renal clearance. SSTR2 expression was added for several organs. Input parameters were fixed or estimated using a built-in Monte Carlo algorithm for parameter identification. RESULTS: 68Ga-DOTATATE was administered with a median peptide amount of 12.3 µg (range 8.05-16.9 µg) labeled with 92.7 MBq (range 43.4-129.9 MBq). SSTR2 amounts for spleen, liver and thyroid were estimated at 4.40, 7.80 and 0.0108 nmol, respectively. Variability in observed organ concentrations was best described by variability in SSTR2 expression and differences in administered peptide amounts. CONCLUSIONS: To conclude, biodistribution of 68Ga-DOTATATE was described with a whole-body PBPK model, where tissue distribution was mainly determined by variability in SSTR2 organ expression and differences in administered peptide amounts.
引用
- Siebinga H, de Wit-van der Veen BJ, Beijnen JH, et al. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. EJNMMI Res. 2021. PMID: 34398356. doi:10.1186/s13550-021-00821-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。